↑Nakamura T; Sanokawa R; Sasaki Y; Ayusawa D; Oishi M; Mori N (November 1996). "N-Shc: a neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway". Oncogene. 13 (6): 1111–21. PMID8808684.
↑Nakamura, T; Muraoka S; Sanokawa R; Mori N (March 1998). "N-Shc and Sck, two neuronally expressed Shc adapter homologs. Their differential regional expression in the brain and roles in neurotrophin and Src signaling". J. Biol. Chem. UNITED STATES. 273 (12): 6960–7. doi:10.1074/jbc.273.12.6960. ISSN0021-9258. PMID9507002.
↑Suzuki, Shingo; Mizutani Masaharu; Suzuki Kenji; Yamada Masashi; Kojima Masami; Hatanaka Hiroshi; Koizumi Shinichi (June 2002). "Brain-derived neurotrophic factor promotes interaction of the Nck2 adaptor protein with the TrkB tyrosine kinase receptor". Biochem. Biophys. Res. Commun. United States. 294 (5): 1087–92. doi:10.1016/S0006-291X(02)00606-X. ISSN0006-291X. PMID12074588.
Pelicci G, Dente L, De Giuseppe A, et al. (1996). "A family of Shc related proteins with conserved PTB, CH1 and SH2 regions". Oncogene. 13 (3): 633–41. PMID8760305.
Menegon A; Leoni C; Benfenati F; Valtorta F (1997). "Tat protein from HIV-1 activates MAP kinase in granular neurons and glial cells from rat cerebellum". Biochem. Biophys. Res. Commun. 238 (3): 800–5. doi:10.1006/bbrc.1997.7393. PMID9325171.
Wang JF, Ganju RK, Liu ZY, et al. (1997). "Signal transduction in human hematopoietic cells by vascular endothelial growth factor related protein, a novel ligand for the FLT4 receptor". Blood. 90 (9): 3507–15. PMID9345034.
Nakamura T; Muraoka S; Sanokawa R; Mori N (1998). "N-Shc and Sck, two neuronally expressed Shc adapter homologs. Their differential regional expression in the brain and roles in neurotrophin and Src signaling". J. Biol. Chem. 273 (12): 6960–7. doi:10.1074/jbc.273.12.6960. PMID9507002.
Tarr PE, Roncarati R, Pelicci G, et al. (2002). "Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc". J. Biol. Chem. 277 (19): 16798–804. doi:10.1074/jbc.M110286200. PMID11877420.
Liu HY; Meakin SO (2002). "ShcB and ShcC activation by the Trk family of receptor tyrosine kinases". J. Biol. Chem. 277 (29): 26046–56. doi:10.1074/jbc.M111659200. PMID12006576.
Miyake I, Hakomori Y, Shinohara A, et al. (2002). "Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines". Oncogene. 21 (38): 5823–34. doi:10.1038/sj.onc.1205735. PMID12185581.
Miyake I, Hakomori Y, Misu Y, et al. (2005). "Domain-specific function of ShcC docking protein in neuroblastoma cells". Oncogene. 24 (19): 3206–15. doi:10.1038/sj.onc.1208523. PMID15735675.
Magrassi L, Conti L, Lanterna A, et al. (2005). "Shc3 affects human high-grade astrocytomas survival". Oncogene. 24 (33): 5198–206. doi:10.1038/sj.onc.1208708. PMID15870690.
De Falco V, Guarino V, Malorni L, et al. (2005). "RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors". Oncogene. 24 (41): 6303–13. doi:10.1038/sj.onc.1208776. PMID15940252.
Li MD, Sun D, Lou XY, et al. (2007). "Linkage and association studies in African- and Caucasian-American populations demonstrate that SHC3 is a novel susceptibility locus for nicotine dependence". Mol. Psychiatry. 12 (5): 462–73. doi:10.1038/sj.mp.4001933. PMID17179996.